You are here

  • Home
  • Archive
  • Volume 10, Issue 3
  • Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Oncolytic and local immunotherapy
Original research
Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: March 2022 to November 2024

AbstractFullPdf
Mar 2022614638187
Apr 2022359376162
May 202214141457225
Jun 202245547063
Jul 202219320145
Aug 202222323357
Sep 202220420948
Oct 202225927071
Nov 202217417450
Dec 202214214243
Jan 202315815845
Feb 202315415444
Mar 202317817983
Apr 202312212247
May 202315916054
Jun 202317517542
Jul 202315816048
Aug 202313113149
Sep 202312612946
Oct 202311411638
Nov 202319719734
Dec 202319620254
Jan 20249910033
Feb 202410310533
Mar 202413313563
Apr 2024878752
May 202410911349
Jun 2024878953
Jul 20249910337
Aug 202414814530
Sep 202415015450
Oct 202418519148
Nov 202419519963
Total730074742046